2017
Immune Checkpoint Inhibition in Lung Cancer
Morgensztern D, Herbst R. Immune Checkpoint Inhibition in Lung Cancer. 2017, 333-344. DOI: 10.1007/978-3-319-62431-0_20.Peer-Reviewed Original ResearchNon-small cell carcinomaSmall cell lung cancerLarge cell carcinomaSquamous cell carcinomaVascular endothelium growth factorLung cancerCell carcinomaEpidermal growth factor receptorMost patientsMetastatic non-small cell carcinomaPlatinum-based chemotherapy doubletsSmall molecule tyrosine kinase inhibitorsMolecule tyrosine kinase inhibitorsAbsence of contraindicationsImmune checkpoint inhibitionProlonged clinical benefitCell lung cancerStandard of careAmerican Cancer SocietyTyrosine kinase inhibitorsChemotherapy doubletsGrowth factor receptorNSCLC presentPalliative intentCheckpoint inhibition
2004
Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors
Tran HT, Blumenschein GR, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemotherapy And Pharmacology 2004, 54: 308-314. PMID: 15184994, DOI: 10.1007/s00280-004-0816-z.Peer-Reviewed Original ResearchConceptsPharmacokinetics of carboplatinTNP-470Solid tumorsDoublet regimenAngiogenesis inhibitor TNP-470Hematological toxic effectsRegimen of paclitaxelCycles of therapyMedian survival durationCombination of paclitaxelPatient survival ratesRecent clinical trialsHead/neckCell lung carcinomaTNP-470 administrationToxic effectsAUC 5AUC 6Chemotherapy doubletsIntravenous paclitaxelPurposePreclinical studiesStable diseasePartial responseRandomized studySurvival duration